Tricida Inc (NASDAQ:TCDA) Director Klaus R. Dr Veitinger sold 3,492 shares of the business’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $36.30, for a total transaction of $126,759.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of TCDA traded up $0.07 during trading hours on Tuesday, hitting $34.20. The stock had a trading volume of 260,471 shares, compared to its average volume of 307,514. The company’s fifty day moving average price is $36.42. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.30 and a quick ratio of 8.30. Tricida Inc has a 52 week low of $19.43 and a 52 week high of $42.80. The stock has a market capitalization of $1.71 billion and a PE ratio of -7.37.
Tricida (NASDAQ:TCDA) last posted its earnings results on Wednesday, May 8th. The company reported ($0.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.10). On average, analysts anticipate that Tricida Inc will post -3.44 EPS for the current fiscal year.
TCDA has been the topic of several analyst reports. Empire upped their target price on shares of Tricida from $37.00 to $58.00 in a report on Monday, April 1st. Goldman Sachs Group initiated coverage on shares of Tricida in a report on Wednesday, June 26th. They issued a “buy” rating and a $48.00 target price on the stock. Needham & Company LLC initiated coverage on shares of Tricida in a report on Friday, May 24th. They issued a “buy” rating and a $50.00 target price on the stock. Cowen reaffirmed a “buy” rating and issued a $50.00 target price on shares of Tricida in a report on Tuesday, June 25th. Finally, Zacks Investment Research raised shares of Tricida from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a report on Saturday, March 30th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $47.00.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.